Compare Gitlab Inc (GTLB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Neurocrine Biosciences Inc — how do they compare? Gitlab Inc trades at $54.71 (market cap $8.92B), while Neurocrine Biosciences Inc trades at $142.78 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Gitlab Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gitlab Inc for 62 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GTLB | NBIX | |
|---|---|---|
Market Cap | $8.92B | $14.36B |
Volume | 4,716,893 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $53.56 | $185.50 |
52-Week Low | $19.42 | $123.10 |
Typical Hold Time | 62 Days | 23 Days |
Enterprise Value | $7.66B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) is trading at $54.74, up 5.29% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings expectations in recent quarters. Revenue growth remains robust at 21.3% year-over-year in Q2 2026, though the company continues to operate at a net loss. Recent news highlights strong AI-driven demand and improved sales momentum, with the company raising its full-year guidance.
The outlook is cautiously optimistic with significant revenue growth potential from AI integration, but high valuation multiples and persistent profitability challenges present risks. Analyst consensus leans neutral with a $49.71 price target below current levels, suggesting limited near-term upside despite positive business developments.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
